COVID-19 coagulopathy vs disseminated intravascular coagulation
In this issue’s Blood Advances Talk (BAT), Levi discusses the topic of the coagulopathy observed in patients with serious COVID-19 infections. He discusses and contrasts the differences between COVID-19 coagulopathic abnormalities and disseminated intravascular coagulation or thrombotic microangiopathy. We hope you find this talk useful to gain further insights into this complication of COVID-19 infection as the pandemic evolves.
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain
The American Society of Hematology has developed clinical guidelines for various aspects of the treatment of patients with sickle cell disease. In the newest guideline article, Brandow and colleagues discuss the important topic of managing acute and chronic pain in these patients.
Hurdles in treating Hurler disease: potential routes to achieve a “real” cure
Mucopolysaccharidoses are a group of often devastating multiorgan diseases treated with either enzyme replacement therapy or allogeneic hematopoietic cell transplantation. Despite these therapies, many obstacles remain to obtain the cure of these disorders. van den Broek and colleagues discuss these issues in a comprehensive review.
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
The choice of which tyrosine kinase inhibitor (TKI) to utilize for newly diagnosed patients with chronic myeloid leukemia is an area of ongoing debate. In a Systematic Review, Vener and colleagues review the use of different TKIs, highlighting important considerations in the choice of agent.
Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis
In a Systematic Review, Patel and colleagues evaluate the outcomes of patients with suspected deep venous thrombosis. This timely evaluation of large randomized clinical trials provides important clinical insights that help guide therapeutic interventions.
Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism
The question of the impact of prophylaxis for venous thromboembolism in patients undergoing neurosurgical intervention is an area of ongoing debate. The Systematic Review by Yepes-Nuñez and colleagues addresses this question through the comprehensive evaluation of current literature.
